1967 - 2007

Specialty clinical pathology laboratory 

  • 1967

    Creation of Laboratoire Cerba  (Centre d’études et de recherches en biologie appliquée): a reference lab that performs clinical pathology on behalf of other public and private laboratories. 

  • 1990

    Creation of Cerba’s anatomocytopathology department 

  • 1992

    Creation of Cerba’s  human genetics department

  • 1998

    Merge with the infectiology expert  Institut Pasteur's specialized clinical pathology centre


    Pasteur-Cerba began the first  european specialized  clinical pathology laboratory  

  • 1999

    COFRAC Accreditation EN CEI ISO 17025: Cerba, first laboratory accredited in France.

  • 2001

    Creation of Cerba’s vet health department

  • 2002

    Development of Cerba’s activities  in Africa and Middle East


New activity and new geographic position: routine activity and clinical trials in Belgium

  • 2007

    Acquisition of Barc Group, clinical pathology leader in Belgium and clinical trials’ global player.

  • Acquisition of CRI and LBS laboratories in Belgium


  • Cerba becomes Cerba European Lab

2009 - 2014

New activity and new geographic positions: routine activity in France and Luxembourg

  • 2009

    Acquisition of Laboratoire Biolille

  • 2010

    Acquisition of Biotop and CBCV

  • 2011

    Acquisition of Bioréunion, Ketterthill, BioPyrénéesLab and Medic Lab laboratories.


  • 2012

    Acquisition of Biobaie and Biopole 80

  • 2013

    Acquisition of CBM 76


    Cerba is the first specialized clinical pathology laboratory in France to perform screening tests for trisomy 13, 18 and 21 by free circulating DNA available to the medical community.


    Launch of Biopredix, first preventive medicine check-ups to preserve health capital.


    Creation of Cerba Specimen Services, branch dedicated to IVD industries.

  • 2014

    Acquisition of CMP, anatomocytopatholgy laboratory in Brussels.

2015 - 2016

New activity: veterinary clinical pathology and genetics

Development of Cerballiance network in France

  • 2015

    Acquisition of Novescia, Bioponant, laboratoires Goelab, Vigibio, Cerdibio et Labo 17


    Cerba European Lab becomes 

    Cerba HealthCare


    Creation of Institut Cerba endowment fund for socially inclusive and responsible clinical pathology


    Creation of Cerba Vet, veterinary clinical pathology laboratory.

  • 2016

    Launch of Cerba HealthCare University, a pioneering initiative in the clinical pathology market.


    Acquisition of Antagene, DNA tests for parentage certification and disease prevention in dogs and cats.


    Creation of Cerballiance network bringing together all the routine laboratories in France


    Cerba is the first private laboratory to perform exome sequencing and thus committed to the diagnosis of rare constitutional genetic diseases


2017 - 2023

New geographic positions: routine clinical pathology in Africa and Italy

New activity: medical imaging in Italy

Development of routine clinical pathologyin France and veterinary clinical pathology in France and Switzerland.

Development of clinical trials activities in Netherlands, Canada and Asia.

  • 2017

    Acquisition of the Italian laboratories Deltamedica et Fleming Research

  • 2018

    Acquisition of BIO 7


    Cerba Specimen Services becomes Cerba Xpert


    Acquisition of  Histalim to strengthen Barc’s expertise in anatomocytopathology


  • 2019

    Launch of Cerba Sport, a complete range of tests to optimize sports performance


    Creation of Cerba Lancet Africa: Group’s establishment in Africa  to develop a network of laboratories in partnership with Lancet Laboratories, South Africa’s leader in clinical pathology


    Lauch of Innov Lab, a platform that enables every employee to post ideas, participate in innovation challenges and get informed about ongoing initiatives and new projetcs throughout the Group

  • 2020

    Barc, Histalim  and Cerba Xpert become Cerba Research, branch dedicated to clinical pathology for clinical trials serving the biotechnology, pharmaceutical and in vitro diagnostics industries.


    Creation of Cerba Path, anatomocytopathology experts’ network.

  • 2021

    Acquisition of the Italian laboratories Lifebrain. Cerba HealthCare becomes the market leader in medical diagnosis in Italy.


    Creation of CerbACT Asia (strategic joint-venture between Cerba Research and ACT Genomics) : a purpose-built lab facility in Taiwan covering the Asia Pacific region.


    Acquisition of Labexa, a leading clinical pathology group in the Nouvelle Aquitaine region.


    Acquisition of Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO).

  • 2022

    Acquisition of Yourlab, a clinical pathology group based in western France.


    Cerba Lancet Africa signs strategic partnership with International Clinical Laboratories in Ethiopia


    Publication of the first CSR report



  • 2023

    Animal Diagnostic, IHP VETO, LAPVSO, Orbio et Scanelis join the Cerba Vet centre of excellence 


    Acquisition of CIRION BioPharma Research (canadian contract research laboratory) to expand the Group’s bioanalytical capabilities and shorten time-to-deploy complex clinical trials


    Creation of Cerba HealthCare Saudi Arabia (strategic joint venture between Cerba HealthCare and Nexus Gulf Healthcare) to contribute to the upcoming transformation of healthcare system in Saudi Arabia